1,986 results on '"Van Hemelrijck, Mieke"'
Search Results
402. Barriers and facilitators to physical activity in men with prostate cancer: A qualitative and quantitative systematic review
- Author
-
Fox, Louis, primary, Wiseman, Theresa, additional, Cahill, Declan, additional, Beyer, Katharina, additional, Peat, Nicola, additional, Rammant, Elke, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2019
- Full Text
- View/download PDF
403. Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts
- Author
-
Drost, Frank-Jan H., primary, Nieboer, Daan, additional, Morgan, Todd M., additional, Carroll, Peter R., additional, Roobol, Monique J., additional, Trock, Bruce, additional, Ehdaie, Behfar, additional, Carroll, Peter, additional, Filson, Christopher, additional, Kim, Jeri, additional, Logothetis, Christopher, additional, Morgan, Todd, additional, Klotz, Laurence, additional, Pickles, Tom, additional, Hyndman, Eric, additional, Moore, Caroline M., additional, Gnanapragasam, Vincent, additional, Van Hemelrijck, Mieke, additional, Dasgupta, Prokar, additional, Bangma, Chris, additional, Roobol, Monique, additional, Villers, Arnauld, additional, Rannikko, Antti, additional, Perry, Antoinette, additional, Hugosson, Jonas, additional, Rubio-Briones, Jose, additional, Bjartell, Anders, additional, Hefermehl, Lukas, additional, Shiong, Lee Lui, additional, Frydenberg, Mark, additional, Kakehi, Yoshiyuki, additional, Chung, Byung Ha, additional, van der Kwast, Theo, additional, van der Linden, Wim, additional, Hulsen, Tim, additional, de Jonge, Cees, additional, Kattan, Mike, additional, Xinge, Ji, additional, Muir, Kenneth, additional, Lophatananon, Artitaya, additional, Fahey, Michael, additional, Steyerberg, Ewout, additional, Zhang, Liying, additional, Beckmann, Kerri, additional, Denton, Brian, additional, Hayen, Andrew, additional, Boutros, Paul, additional, Guo, Wei, additional, Benfante, Nicole, additional, Cowan, Janet, additional, Patil, Dattatraya, additional, Tolosa, Emily, additional, Kim, Tae-Kyung, additional, Mamedov, Alexandre, additional, LaPointe, Vincent, additional, Crump, Trafford, additional, Kimberly-Duffell, Jenna, additional, Santaolalla, Aida, additional, Olivier, Jonathan, additional, Rancati, Tiziana, additional, Ahlgren, Helén, additional, Mascarós, Juanma, additional, Löfgren, Annica, additional, Lehmann, Kurt, additional, Han Lin, Catherine, additional, Hirama, Hiromi, additional, Suk Lee, Kwang, additional, Jenster, Guido, additional, Auvinen, Anssi, additional, Haider, Masoom, additional, van Bochove, Kees, additional, Carter, Ballentine, additional, Gledhill, Sam, additional, Buzza, Mark, additional, Bruinsma, Sophie, additional, and Helleman, Jozien, additional
- Published
- 2019
- Full Text
- View/download PDF
404. Scoping review protocol: is there a role for physical activity interventions in the treatment pathway of bladder cancer?
- Author
-
Mehrotra, Sneha, primary, Rowland, Megan, additional, Zhang, Hanyu, additional, Russell, Beth, additional, Fox, Louis, additional, Beyer, Katharina, additional, Rammant, Elke, additional, Peat, Nicola, additional, Van Hemelrijck, Mieke, additional, and Bosco, Cecilia, additional
- Published
- 2019
- Full Text
- View/download PDF
405. Circulating uric acid levels and subsequent development of cancer in 493,281 individuals: findings from the AMORIS Study
- Author
-
Yiu, Andrew, Van Hemelrijck, Mieke, Garmo, Hans, Holmberg, Lars, Malmström, Håkan, Lambe, Mats, Hammar, Niklas, Walldius, Göran, Jungner, Ingmar, and Wulaningsih, Wahyu
- Subjects
Male ,Sweden ,Cancer och onkologi ,Incidence ,Uric Acid ,Social Class ,Cancer and Oncology ,Neoplasms ,Population Surveillance ,cancer ,Humans ,Female ,Prospective study ,Uric acid ,Cancer ,Research Paper ,prospective study ,Follow-Up Studies ,Proportional Hazards Models - Abstract
Objectives: Serum uric acid has been suggested to be associated with cancer risk. We aimed to study the association between serum uric acid and cancer incidence in a large Swedish cohort. Results: A positive association was found between uric acid levels and overall cancer risk, and results were similar with adjustment for glucose, triglycerides and BMI. Hazard ratio (HR) for overall cancer for the 4th quartile of uric acid compared to the 1st was 1.08 (95% CI: 1.05-1.11) in men and 1.12 (1.09 - 1.16) in women. Site-specific analysis showed a positive association between uric acid and risk of colorectal, hepatobiliary, kidney, nonmelanoma skin, and other cancers in men and of head and neck and other cancers in women. An inverse association was observed for pulmonary and central nervous system (CNS) cancers in men and breast, lymphatic and haematological, and CNS malignancies in women. Materials and Methods: We included 493,281 persons aged 20 years and older who had a measurement of serum uric acid and were cancer-free at baseline in the AMORIS study. Multivariable Cox proportional hazards regression was used to investigate sex-specific quartiles of serum uric acid in relation to cancer risk in men and women. Analysis was further adjusted for serum glucose, triglycerides and, where available, BMI. Site-specific analysis was performed for major cancers. Conclusions: Altered uric acid levels were associated with risk of overall and some specific cancers, further indicating the potential role of uric acid metabolism in carcinogenesis.
- Published
- 2017
406. Trends observed during a decade of paediatric sick visits to peripheral health facilities in rural western Kenya, 1997–2006
- Author
-
Van Hemelrijck, Mieke J. J., Lindblade, Kim A., Kubaje, Adazu, Hamel, Mary J., Odhiambo, Frank, Phillips-Howard, Penelope A., Laserson, Kayla F., Slutsker, Laurence, and Feikin, Daniel R.
- Published
- 2009
407. Erratum to “Effect of Simulation-based Training on Surgical Proficiency and Patient Outcomes: A Randomised Controlled Clinical and Educational Trial” [Eur Urol 2022;81:385–393]
- Author
-
Baig, Umair, Aya, Haleema, Husnain Iqbal, Mohammed, Kum, Francesca, Bultitude, Matthew, Glass, Jonathan, Khan, Azhar, Makanjuola, Jonathan, McCabe, John E., Samsuddin, Azi, McIlhenny, Craig, Brewin, James, Kulkarni, Shashank, Khwaja, Sikandar, Islam, Waliul, Marsh, Howard, Bhat, Taher, Thomas, Benjamin, Cutress, Mark, Housami, Fadi, Nedas, Timothy, Bates, Timothy, Mukherjee, Rono, Graham, Stuart, Bordenave, Matthieu, Coker, Charles, Ahmed, Shwan, Symes, Andrew, Calvert, Robert, Lynch, Ciaran, Long, Ronan, Patterson, Jacob M., Rukin, Nicholas J., Khan, Shahid A., Dasgupta, Ranan, Brown, Stephen, Grey, Ben, Mahmalji, Waseem, Lam, Wayne, Scheitlin, Walter, Saelzler, Norbert, Fiedler, Marcel, Ishikawa, Shuhei, Sasaki, Yoshihiro, Sazawa, Ataru, Shinno, Yuichiro, Mochizuki, Tango, Peter Jessen, Jan, Steiner, Roland, Wendt-Nordahl, Gunnar, Atassi, Nabil, Kohns, Heiko, Cox, Ashley, Rendon, Ricardo, Lawen, Joseph, Bailly, Greg, Marsh, Trevor, Aydın, Abdullatif, Ahmed, Kamran, Abe, Takashige, Raison, Nicholas, Van Hemelrijck, Mieke, Garmo, Hans, Ahmed, Hashim U., Mukhtar, Furhan, Al-Jabir, Ahmed, Brunckhorst, Oliver, Shinohara, Nobuo, Zhu, Wei, Zeng, Guohua, Sfakianos, John P., Gupta, Mantu, Tewari, Ashutosh, Serdar Gözen, Ali, Rassweiler, Jens, Skolarikos, Andreas, Kunit, Thomas, Knoll, Thomas, Moltzahn, Felix, Thalmann, George N., Lantz Powers, Andrea G., Chew, Ben H., Sarica, Kemal, Shamim Khan, Muhammad, and Dasgupta, Prokar
- Published
- 2022
- Full Text
- View/download PDF
408. Outcomes of head and neck cancer management from two cancer centres in Southern and Northern Europe during the first wave of COVID-19
- Author
-
Tagliabue, Marta, Russell, Beth, Moss, Charlotte, De Berardinis, Rita, Chu, Francesco, Jeannon, Jean-Pierre, Pietrobon, Giacomo, Haire, Anna, Grosso, Enrica, Wylie, Harriet, Zorzi, Stefano, Proh, Michele, Brunet-Garcia, Aina, Cattaneo, Augusto, Oakley, Richard, De Benedetto, Luigi, Arora, Asit, Riccio, Stefano, Fry, Alistair, Bruschini, Roberto, Townley, William, Giugliano, Gioacchino, Orfaniotis, Georgios, Madini, Marzia, Dolly, Saoirse, Borghi, Ester, Aprile, Danila, Zurlo, Valeria, Bibiano, Debora, Mastrilli, Fabrizio, Chiocca, Susanna, Van Hemelrijck, Mieke, Gandini, Sara, Simo, Ricard, and Ansarin, Mohssen
- Abstract
Objective: To describe the approach and outcomes from two cancer centres in Southern and Northern Europe during the first wave of coronavirus disease 2019 (COVID-19) of patients with head and neck cancer (HNC).Methods: Data collection was performed on a retrospective cohort of patients surgically treated for primary HNC between March and May 2020, using data from two tertiary hospitals: the European Institute of Oncology (Milan) and Guy’s & St Thomas’ NHS Foundation Trust (London).Results: We included 77 patients with HNC. More patients with COVID-19 were taking angiotensin-converting enzyme (ACE) inhibitors and had Clavien-Dindo Classification grade I compared to negative patients, respectively (60% vs 22% [p= 0.058] and 40% vs 8% [p= 0.025]). Multivariate logistic regression analyses confirmed our data (p= 0.05 and 0.03, respectively). Sex and age were statistically significantly different (p= 0.05 and <0.001 respectively), showing more male patients (75% vs 53.66%, respectively) and more elderly patients in Italy than in the United Kingdom (patients aged >63 years: 69.44% vs 29.27%).Conclusions: This study presents a large cohort of patients with HNC with nasopharyngeal swab during the first peak of the COVID-19 pandemic in Europe. Patients with HNC with COVID-19 appeared more likely to develop postsurgical complications and to be taking ACE inhibitors. The preventive measures adopted guaranteed the continuation of therapeutic surgical intervention.
- Published
- 2022
- Full Text
- View/download PDF
409. Metabolic profiles to predict long-term cancer and mortality: the use of latent class analysis
- Author
-
Santaolalla, Aida, Garmo, Hans, Grigoriadis, Anita, Ghuman, Sundeep, Hammar, Niklas, Jungner, Ingmar, Walldius, Göran, Lambe, Mats, Holmberg, Lars, and Van Hemelrijck, Mieke
- Subjects
Adult ,Male ,Disease susceptibility ,Carcinogenesis ,Iron ,Cancer epidemiology ,Risk Factors ,Latent class analysis ,Neoplasms ,Biomarkers, Tumor ,Humans ,Prospective Studies ,lcsh:QH573-671 ,Risk stratification ,Aged ,Proportional Hazards Models ,Inflammation ,Sweden ,lcsh:Cytology ,Middle Aged ,Lipid Metabolism ,Liver ,Metabolic profiles ,Metabolome ,Female ,Biomarkers ,Research Article ,Follow-Up Studies - Abstract
Background Metabolites are genetically and environmentally determined. Consequently, they can be used to characterize environmental exposures and reveal biochemical mechanisms that link exposure to disease. To explore disease susceptibility and improve population risk stratification, we aimed to identify metabolic profiles linked to carcinogenesis and mortality and their intrinsic associations by characterizing subgroups of individuals based on serum biomarker measurements. We included 13,615 participants from the Swedish Apolipoprotein MOrtality RISk Study who had measurements for 19 biomarkers representative of central metabolic pathways. Latent Class Analysis (LCA) was applied to characterise individuals based on their biomarker values (according to medical cut-offs), which were then examined as predictors of cancer and death using multivariable Cox proportional hazards models. Results LCA identified four metabolic profiles within the population: (1) normal values for all markers (63% of population); (2) abnormal values for lipids (22%); (3) abnormal values for liver functioning (9%); (4) abnormal values for iron and inflammation metabolism (6%). All metabolic profiles (classes 2–4) increased risk of cancer and mortality, compared to class 1 (e.g. HR for overall death was 1.26 (95% CI: 1.16–1.37), 1.67 (95% CI: 1.47–1.90), and 1.21 (95% CI: 1.05–1.41) for class 2, 3, and 4, respectively). Conclusion We present an innovative approach to risk stratify a well-defined population based on LCA metabolic-defined subgroups for cancer and mortality. Our results indicate that standard of care baseline serum markers, when assembled into meaningful metabolic profiles, could help assess long term risk of disease and provide insight in disease susceptibility and etiology. Electronic supplementary material The online version of this article (10.1186/s12860-019-0210-7) contains supplementary material, which is available to authorized users.
- Published
- 2019
410. Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma
- Author
-
Nakamura, Mano, Bax, Heather J., Scotto, Daniele, Souri, Elmira Amiri, Sollie, Sam, Harris, Robert J., Hammar, Niklas, Walldius, Goran, Winship, Anna, Ghosh, Sharmistha, Montes, Ana, Spicer, James F., Van Hemelrijck, Mieke, Josephs, Debra H., Lacy, Katie E., Tsoka, Sophia, and Karagiannis, Sophia N.
- Subjects
lcsh:Immunologic diseases. Allergy ,Immune activation ,ovarian cancer ,immune mediators ,inflammation ,M1/M2 ,biomarkers ,Th1/Th2/Th17 ,lcsh:RC581-607 ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,lcsh:RC254-282 ,Original Research - Abstract
Immune and inflammatory cascades may play multiple roles in ovarian cancer. We aimed to identify relationships between expression of immune and inflammatory mediators and patient outcomes. We interrogated differential gene expression of 44 markers and marker combinations (n = 1,978) in 1,656 ovarian carcinoma patient tumors, alongside matched 5-year overall survival (OS) data in silico. Using machine learning methods, we investigated whether genomic expression of these 44 mediators can discriminate between malignant and non-malignant tissues in 839 ovarian cancer and 115 non-malignant ovary samples. We furthermore assessed inflammation markers in 289 ovarian cancer patients’ sera in the Swedish Apolipoprotein MOrtality-related RISk (AMORIS) cohort. Expression of the 44 mediators could discriminate between malignant and non-malignant tissues with at least 96% accuracy. Higher expression of classical Th1, Th2, Th17, anti-parasitic/infection and M1 macrophage mediator signatures were associated with better OS. Contrastingly, inflammatory and angiogenic mediators, CXCL-12, C-reactive protein (CRP) and platelet-derived growth factor subunit A (PDGFA) were negatively associated with OS. Of the serum inflammatory markers in the AMORIS cohort, women with ovarian cancer who had elevated levels of haptoglobin (≥1.4 g/L) had a higher risk of dying from ovarian cancer compared to those with haptoglobin levels
- Published
- 2019
411. Reasons for Discontinuing Active Surveillance: Assessment of 21 Centres in 12 Countries in the Movember GAP3 Consortium
- Author
-
Van Hemelrijck, Mieke, Ji, Xi, Helleman, Jozien, Roobol, Monique J, van der Linden, Wim, Nieboer, Daan, Bangma, Chris H, Frydenberg, Mark, Rannikko, Antti, Lee, Lui S, Gnanapragasam, Vincent J, Kattan, Mike W, and Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium
- Subjects
Male ,Urologic Diseases ,Aging ,Time Factors ,Patient Dropouts ,Asia ,Biopsy ,Clinical Decision-Making ,Clinical Sciences ,Active surveillance ,Discontinuation ,Risk Assessment ,Databases ,Risk Factors ,Predictive Value of Tests ,Members of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance GAP3 consortium ,Cause of Death ,Humans ,Watchful Waiting ,Factual ,Early Detection of Cancer ,Aged ,Cancer ,Prostate cancer ,Prevention ,Australia ,Prostatic Neoplasms ,Prostate-Specific Antigen ,Middle Aged ,Urology & Nephrology ,Europe ,Good Health and Well Being ,North America ,Disease Progression ,Kallikreins ,Worldwide - Abstract
BackgroundCareful assessment of the reasons for discontinuation of active surveillance (AS) is required for men with prostate cancer (PCa).ObjectiveUsing Movember's Global Action Plan Prostate Cancer Active Surveillance initiative (GAP3) database, we report on reasons for AS discontinuation.Design, setting, and participantsWe compared data from 10296 men on AS from 21 centres across 12 countries.Outcome measurements and statistical analysisCumulative incidence methods were used to estimate the cumulative incidence rates of AS discontinuation.Results and limitationsDuring 5-yr follow-up, 27.5% (95% confidence interval [CI]: 26.4-28.6%) men showed signs of disease progression, 12.8% (95% CI: 12.0-13.6%) converted to active treatment without evidence of progression, 1.7% (95% CI: 1.5-2.0%) continued to watchful waiting, and 1.7% (95% CI: 1.4-2.1%) died from other causes. Of the 7049 men who remained on AS, 2339 had follow-up for >5yr, 4561 had follow-up for
- Published
- 2019
412. PCASTt/SPCG-17-a randomised trial of active surveillance in prostate cancer : rationale and design
- Author
-
Ahlberg, Mats Steinholtz, Adami, Hans-Olov, Beckmann, Kerri, Bertilsson, Helena, Bratt, Ola, Cahill, Declan, Egevad, Lars, Garmo, Hans, Holmberg, Lars, Johansson, Eva, Rannikko, Antti, Van Hemelrijck, Mieke, Jaderling, Fredrik, Wassberg, Cecilia, Åberg, Ulrika W. N., Bill-Axelson, Anna, University of Helsinki, Department of Surgery, University Management, Urologian yksikkö, and HUS Abdominal Center
- Subjects
ACCURACY ,education ,3122 Cancers ,active surveillance ,3126 Surgery, anesthesiology, intensive care, radiology ,prostate cancer ,randomised trial ,LIFE ,3121 General medicine, internal medicine and other clinical medicine ,Urologi och njurmedicin ,Urology and Nephrology ,FOLLOW-UP ,VERSION ,MRI - Abstract
Introduction Overtreatment of localised prostate cancer is substantial despite increased use of active surveillance. No randomised trials help define how to monitor patients or when to initiate treatment with curative intent. Methods and analysis A randomised, multicentre, intervention trial designed to evaluate the safety of an MRI-based active surveillance protocol, with standardised triggers for repeated biopsies and radical treatment. The aim is to reduce overtreatment of prostate cancer. 2000 men will be randomly allocated to either surveillance according to current practice or to standardised triggers at centres in Sweden, Norway, Finland and the UK. Men diagnosed in the past 12 months with prostate cancer, ≤T2a, prostate-specific antigen (PSA)
- Published
- 2019
413. Survival after radiotherapy versus radical cystectomy for primary muscle-invasive bladder cancer: A Swedish nationwide population-based cohort study
- Author
-
Häggström, Christel, Garmo, Hans, de Luna, Xavier, Van Hemelrijck, Mieke, Söderkvist, Karin, Aljabery, Firas, Ströck, Viveka, Hosseini, Abolfazl, Gårdmark, Truls, Malmström, Per-Uno, Jahnson, Staffan, Liedberg, Fredrik, and Holmberg, Lars
- Subjects
Cancer och onkologi ,Cancer and Oncology ,Urologi och njurmedicin ,bladder cancer ,Urology and Nephrology ,radical cystectomy ,muscle-invasive ,radiotherapy ,urothelial carcinoma - Abstract
Background Studies of survival comparing radical cystectomy (RC) and radiotherapy for muscle-invasive bladder cancer have provided inconsistent results and have methodological limitations. The aim of the study was to investigate risk of death after radiotherapy as compared to RC. Methods We selected patients with muscle-invasive urothelial carcinoma without distant metastases, treated with radiotherapy or RC from 1997 to 2014 in the Bladder Cancer Data Base Sweden (BladderBaSe) and estimated absolute and relative risk of bladder cancer death and all-cause death. In a group of patients, theoretically eligible for a trial comparing radiotherapy and RC, we calculated risk difference in an instrumental variable analysis. We have not investigated chemoradiotherapy as this treatment was not used in the study time period. Results The study included 3 309 patients, of those 17% were treated with radiotherapy and 83% with RC. Patients treated with radiotherapy were older, had more advanced comorbidity, and had a higher risk of death as compared to patients treated with RC (relative risks of 1.5-1.6). In the "trial population," all-cause death risk difference was 6 per 100 patients lower after radiotherapy at 5 years of follow-up, 95% confidence interval -41 to 29. Conclusion(s) Patient selection between the treatments make it difficult to evaluate results from conventionally adjusted and propensity-score matched survival analysis. When taking into account unmeasured confounding by instrumental variable analysis, no differences in survival was found between the treatments for a selected group of patients. Further clinical studies are needed to characterize this group of patients, which can serve as a basis for future comparison studies for treatment recommendations. Funding Agencies|Swedish Cancer Society [CAN 2013/472]
- Published
- 2019
414. Erratum: Progression of breast cancer following locoregional ipsilateral recurrence: importance of interval time
- Author
-
Melvin, Jennifer C, Purushotham, Arnie D, Garmo, Hans, Pinder, Sarah E, Fentiman, Ian S, Gillett, Cheryl, Mera, Anca, Lüchtenborg, Margreet, Holmberg, Lars, and Van Hemelrijck, Mieke
- Published
- 2016
- Full Text
- View/download PDF
415. Anti-androgen monotherapy versus gonadotropin-releasing hormone agonists in men with advanced, non-metastatic prostate cancer : a register-based, observational study
- Author
-
Thomsen, Frederik Birkebaek, Bosco, Cecilia, Garmo, Hans, Adolfsson, Jan, Hammar, Niklas, Stattin, Pär, Van Hemelrijck, Mieke, Thomsen, Frederik Birkebaek, Bosco, Cecilia, Garmo, Hans, Adolfsson, Jan, Hammar, Niklas, Stattin, Pär, and Van Hemelrijck, Mieke
- Abstract
Background: In randomised controlled trials, men with advanced, non-metastatic prostate cancer (PCa) treated with anti-androgen monotherapy (AA) had similar all-cause mortality as men treated with gonadotropin-releasing hormone (GnRH) agonists. Using real-world evidence (i.e., observational data), we aimed to further assess the difference in mortality between these two drug categories. Material and Methods: We emulated a trial using data from Prostate Cancer data Base Sweden 3.0. We specifically focused on men diagnosed in 2006-2012 with high-risk PCa who had no distant metastasis. They either received primary hormonal therapy with AA (n=2078) or GnRH agonists (n=4878) who were followed for a median time of 5 years. Risk of death from PCa and other causes was assessed using competing risk analyses and Cox proportional hazards regression analyses, including propensity score matching. Results: The cumulative 5-year PCa mortality was lower for men treated with AA (16% [95% confidence interval, CI, 15-18%]) than men treated with GnRH agonists (22% [95% CI 21-24%]). The 5-year other cause mortality was also lower for men on AA (17% [95% CI 15-19%] compared to men on GnRH agonists (27% [95% CI 25-28%]). In regression analyses, the risk of PCa death was similar, GnRH agonists versus AA (reference), hazard ratio (HR) 1.08 (95% CI 0.95-1.23), but the risk of death from all causes was higher for men on GnRH agonists, HR 1.23 (95% CI 1.13-1.34). Consistent results were seen in the propensity score-matched cohort. Conclusion: Our results indicate that the use of AA as primary hormonal therapy in men with high-risk non-metastatic PCa does not increase PCa-specific mortality compared to GnRH. Using AA instead of GnRH agonists may result in shorter time on/exposure to GnRH-treatment, which may reduce the risk of adverse events associated with this treatment.
- Published
- 2019
- Full Text
- View/download PDF
416. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method
- Author
-
Bessa, Agustina, Maclennan, Steven, Enting, Deborah, Bryan, Richard, Josephs, Debra, Hughes, Simon, Amery, Suzanne, Khan, Muhammad Shamim, Malde, Sachin, Nair, Rajesh, Cahill, Fidelma, Wylie, Harriet, Thurairaja, Ramesh, Chatterton, Kathryn, Kinsella, Netty, Häggström, Christel, Van Hemelrijck, Mieke, Bessa, Agustina, Maclennan, Steven, Enting, Deborah, Bryan, Richard, Josephs, Debra, Hughes, Simon, Amery, Suzanne, Khan, Muhammad Shamim, Malde, Sachin, Nair, Rajesh, Cahill, Fidelma, Wylie, Harriet, Thurairaja, Ramesh, Chatterton, Kathryn, Kinsella, Netty, Häggström, Christel, and Van Hemelrijck, Mieke
- Published
- 2019
- Full Text
- View/download PDF
417. Chronic inflammatory diseases, anti-inflammatory medications and risk of prostate cancer : a population-based case-control study
- Author
-
Beckmann, Kerri, Russell, Beth, Josephs, Debra, Garmo, Hans, Häggström, Christel, Holmberg, Lars, Stattin, Pär, Van Hemelrijck, Mieke, Adolfsson, Jan, Beckmann, Kerri, Russell, Beth, Josephs, Debra, Garmo, Hans, Häggström, Christel, Holmberg, Lars, Stattin, Pär, Van Hemelrijck, Mieke, and Adolfsson, Jan
- Abstract
Background: Whether chronic inflammation increases prostate cancer risk remains unclear. This study investigated whether chronic inflammatory diseases (CID) or anti-inflammatory medication use (AIM) were associated with prostate cancer risk. Methods: Fifty-five thousand nine hundred thirty-seven cases (all prostate cancer, 2007-2012) and 279,618 age-matched controls were selected from the Prostate Cancer Database Sweden. CIDs and AIMs was determined from national patient and drug registers. Associations were investigated using conditional logistic regression, including for disease/drug subtypes and exposure length/dose. Results: Men with a history of any CID had slightly increased risk of any prostate cancer diagnosis (OR: 1.08; 95%CI: 1.04-1.12) but not unfavourable' (high-risk or advanced) prostate cancer. Generally, risk of prostate cancer was highest for shorter exposure times. However, a positive association was observed for asthma >5years before prostate cancer diagnosis (OR: 1.21; 95%CI: 1.05-1.40). Risk of prostate cancer was increased with prior use of any AIMs (OR: 1.26; 95%CI: 1.24-1.29). A positive trend with increasing cumulative dose was only observed for inhaled glucocorticoids (p<0.011). Conclusion: Detection bias most likely explains the elevated risk of prostate cancer with prior history of CIDs or use of AIMs, given the higher risk immediately after first CID event and lack of dose response. However, findings for length of time with asthma and dose of inhaled glucocorticoids suggest that asthma may increase risk of prostate cancer through other pathways.
- Published
- 2019
- Full Text
- View/download PDF
418. Serum glucose, triglycerides, and cholesterol in relation to prostate cancer death in the Swedish AMORIS study
- Author
-
Arthur, Rhonda, Møller, Henrik, Garmo, Hans, Häggström, Christel, Holmberg, Lars, Stattin, Pär, Malmström, Håkan, Lambe, Mats, Hammar, Niklas, Walldius, Göran, Robinson, David, Jungner, Ingmar, Van Hemelrijck, Mieke, Arthur, Rhonda, Møller, Henrik, Garmo, Hans, Häggström, Christel, Holmberg, Lars, Stattin, Pär, Malmström, Håkan, Lambe, Mats, Hammar, Niklas, Walldius, Göran, Robinson, David, Jungner, Ingmar, and Van Hemelrijck, Mieke
- Abstract
Purpose: Lifestyle-related conditions such as obesity are associated with prostate cancer progression, but the associations with hyperglycemia and dyslipidemia are unclear. This study, therefore, aims to examine the association of glucose, triglycerides, and total cholesterol with prostate cancer death Methods: From the Swedish AMORIS cohort, we selected 14,150 men diagnosed with prostate cancer between 1996 and 2011 who had prediagnostic measurements of serum glucose, triglycerides, and total cholesterol. Multivariable Cox proportional hazards regressionmodels were used to determine the hazard ratios for death in relation to the aforementioned metabolic markers. Results: Using clinical cut-off points, a non-significant positive association was observed between glucose and prostate cancer death. When compared to those with glucose in the lowest quartile, those in the highest quartile had greater risk of prostate cancer death (HR 1.19; 95% CI 1.02-1.39). However, neither total cholesterol nor triglycerides were associated with prostate cancer death. Glucose and triglycerides were positively associated with overall, cardiovascular, and other deaths. Hypercholesterolemia was only associated with risk of CVD death. Conclusion: Our results suggest that glucose levels may influence prostate cancer survival, but further studies using repeated measurements are needed to further elucidate how glucose levels may influence prostate cancer progression.
- Published
- 2019
- Full Text
- View/download PDF
419. Neoadjuvant chemotherapy for muscle invasive bladder cancer : a nationwide investigation on survival
- Author
-
Russell, Beth, Sherif, Amir, Häggström, Christel, Josephs, Debra, Kumar, Pardeep, Malmström, Per-Uno, Van Hemelrijck, Mieke, Russell, Beth, Sherif, Amir, Häggström, Christel, Josephs, Debra, Kumar, Pardeep, Malmström, Per-Uno, and Van Hemelrijck, Mieke
- Abstract
Objectives: Randomised controlled trials (RCTs) have investigated the use of neoadjuvant chemotherapy (NAC) and its effect on survival patients with non-metastatic muscle-invasive bladder cancer (MIBC). However, these RCTs have limited external validity and generalisability and, therefore, the current study aims to use real world evidence in the form of observational data to identify the effect that NAC may have on survival, compared to the use of radical cystectomy (RC) alone. Materials and methods: The study cohort (consisting of 944 patients) was selected as a target trial from the Bladder Cancer Data Base Sweden (BladderBaSe). This study calculated 5-year survival and risk of bladder cancer (BC)-specific and overall death by Cox proportional hazard models for the study cohort and a propensity score (PS) matched cohort. Results: Those who had received NAC had higher 5-year survival proportions and decreased risk of both overall and BC specific death (HR = 0.71, 95% CI = 0.52-0.97 and HR = 0.67, 95% CI = 0.48-0.94), respectively, as compared to patients who did not receive NAC. The PS matched cohort showed similar estimates, but with larger statistical uncertainty (Overall death: HR = 0.76, 95% CI = 0.53-1.09 and BC-specific death: HR = 0.73, 95% CI = 0.50-1.07). Conclusion: Results from the current observational study found similar point estimates for 5-year survival and of relative risks as previous studies. However, the results based on real world evidence had larger statistical variability, resulting in a non-statistically significant effect of NAC on survival. Future studies with detailed validated data can be used to further investigate the effect of NAC in narrower patient groups.
- Published
- 2019
- Full Text
- View/download PDF
420. Androgen deprivation therapy for prostate cancer and risk of dementia
- Author
-
Robinson, David, Garmo, Hans, Van Hemelrijck, Mieke, Damber, Jan-Erik, Bratt, Ola, Holmberg, Lars, Wahlund, Lars-Olof, Stattin, Pär, Adolfsson, Jan, Robinson, David, Garmo, Hans, Van Hemelrijck, Mieke, Damber, Jan-Erik, Bratt, Ola, Holmberg, Lars, Wahlund, Lars-Olof, Stattin, Pär, and Adolfsson, Jan
- Abstract
Objectives To study whether androgen deprivation therapy (ADT), the mainstay treatment for advanced and disseminated prostate cancer, is associated with risk of dementia. Methods Risk of dementia in men with prostate cancer primarily managed with ADT or watchful waiting (WW) in the Prostate Cancer Database Sweden, PCBaSe, was compared with that in prostate cancer-free men, matched on birth year and county of residency. We used Cox regression to calculate the hazard ratios (HRs) for Alzheimer's and non-Alzheimer's dementia (vascular dementia, dementia secondary to other diseases or unspecified dementias) for different types and duration of ADT and oral antiandrogens (AAs) as well as for men managed with WW. Results A total of 25 967 men with prostate cancer and 121 018 prostate cancer-free men were followed for a median of 4 years. In both groups 6% of the men were diagnosed with dementia. In men with prostate cancer, gonadotropin-releasing hormone agonist treatment ( HR 1.15, 95% confidence interval [CI] 1.07-1.23) and orchiectomy (HR 1.60, 95% CI 1.32-1.93) were associated with an increased risk of dementia, as compared to no treatment in prostate cancer-free men; however, this increase in risk was only observed for non-Alzheimer's dementia and occurred from year 1-4 after start of ADT. No increase in risk for any type of dementia was observed for men treated with AAs or for men on WW. Conclusion This population-based cohort study does not support previous observations of an increased risk of Alzheimer's dementia for men on ADT; however, there was a small increase in risk of non-Alzheimer's dementia.
- Published
- 2019
- Full Text
- View/download PDF
421. How to measure temporal changes in care pathways for chronic diseases using health care registry data
- Author
-
Ventimiglia, Eugenio, Van Hemelrijck, Mieke, Lindhagen, Lars, Stattin, Pär, Garmo, Hans, Ventimiglia, Eugenio, Van Hemelrijck, Mieke, Lindhagen, Lars, Stattin, Pär, and Garmo, Hans
- Abstract
Background: Disease trajectories for chronic diseases can span over several decades, with several time-dependent factors affecting treatment decisions. Thus, there is a need for long-term predictions of disease trajectories to inform patients and healthcare professionals on the long-term outcomes and provide information on the need of future health care. Here, we propose a state transition model to describe and predict disease trajectories up to 25 years after diagnosis in men with prostate cancer (PCa), as a proof of principle. Methods: States, state transitions, and transition probabilities were identified and estimated in Prostate Cancer data Base of Sweden (PCBaSeTraject), using nationwide population-based data from 118,743 men diagnosed with PCa. A state transition model in discrete time steps (i.e., 4 weeks) was developed and applied to capture all possible transitions (PCBaSeSim). Transition probabilities were estimated for changes in both treatment and comorbidity. These models combined yielded parameter estimates to run an individual-level simulation based on the state-transition model to obtain prediction estimates. Predicted estimates were then compared to real world data in PCBaSeTraject. Results: PCBaSeSim estimates for the cumulative incidence of first and second transitions, death from PCa and death from other causes were compared to observed transitions in PCBaSeTraject. A good agreement was found between simulated and observed estimates. Conclusions: We developed a reliable and accurate simulation tool, PCBaSeSim that provides information on disease trajectories for subjects with a chronic disease on an individual and population-based level.
- Published
- 2019
- Full Text
- View/download PDF
422. Baseline serum folate, vitamin B12 and the risk of prostate and breast cancer using data from the Swedish AMORIS cohort
- Author
-
Essen, Anneli, Santaolalla, Aida, Garmo, Hans, Hammar, Niklas, Walldius, Göran, Jungner, Ingmar, Malmström, Håkan, Holmberg, Lars, Van Hemelrijck, Mieke, Essen, Anneli, Santaolalla, Aida, Garmo, Hans, Hammar, Niklas, Walldius, Göran, Jungner, Ingmar, Malmström, Håkan, Holmberg, Lars, and Van Hemelrijck, Mieke
- Abstract
Purpose: The roles of folate and vitamin B12 in prostate cancer (PCa) or breast cancer (BC) development are unclear. We investigated their roles using the prospective Swedish Apolipoprotein MOrtality RISk (AMORIS) study. Methods: 8,783 men and 19,775 women with vitamin B12 and folate serum measurements were included. Their associations with PCa and BC risk categories were evaluated using Cox proportional hazards regression. Results: During mean follow-up of 13years, 703 men developed PCa. There was an inverse association between folate>32nmol/L and high-risk PCa [hazard ratio (HR) 0.12, 95% confidence interval (CI) 0.02-0.90], and a positive association between folate<5nmol/L and metastatic PCa (HR 5.25, 95% CI 1.29-21.41), compared with folate 5-32nmol/L. No associations with vitamin B12 were found. 795 women developed BC during mean follow-up of 14years. When restricting to the fasting population, there was a positive association between folate>32nmol/L and BC (HR 1.47, 95% CI 1.06-2.04). Conclusion: High folate levels may protect against PCa and low folate levels may increase risk of metastatic PCa. High fasting folate levels may be associated with an increased BC risk. Vitamin B12 was not found to be linked with risk of PCa or BC. Longitudinal studies with serum and dietary information could help define new prevention targets and add information on the role of folate fortification.
- Published
- 2019
- Full Text
- View/download PDF
423. Androgen Deprivation Therapies and Changes in Comorbidity : A Comparison of Gonadotropin-releasing Hormone Agonists and Antiandrogen Monotherapy as Primary Therapy in Men with High-risk Prostate Cancer
- Author
-
Beckmann, Kerri, Garmo, Hans, Adolfsson, Jan, Bosco, Cecilia, Johansson, Eva, Robinson, David, Holmberg, Lars, Stattin, Pär, Van Hemelrijck, Mieke, Beckmann, Kerri, Garmo, Hans, Adolfsson, Jan, Bosco, Cecilia, Johansson, Eva, Robinson, David, Holmberg, Lars, Stattin, Pär, and Van Hemelrijck, Mieke
- Abstract
Background: Some studies suggest that gonadotropin-releasing hormone (GnRH) agonists are associated with higher risk of adverse events than antiandrogens (AAs) monotherapy. However, it has been unclear whether this is due to indication bias. Objective: To investigate rates of change in comorbidity for men on GnRH agonists versus AA monotherapy in a population-based register study. Design, setting, and participants: Men with advanced nonmetastatic prostate cancer (PCa) who received primary AA (n = 2078) or GnRH agonists (n = 4878) and age- and area-matched PCa-free men were selected from Prostate Cancer Database Sweden 3.0. Increases in comorbidity were measured using the Charlson Comorbidity Index (CCI), from 5 yr before through to 5 yr after starting androgen deprivation therapy (ADT). Outcome measures and statistical methods: Multivariable linear regression was used to determine differences in excess rate of CCI change before and after ADT initiation. Risk of any incremental change in CCI following ADT was assessed using multivariable Cox regression analyses. Results and limitations: Men on GnRH agonists experienced a greater difference in excess rate of CCI change after starting ADT than men on AA monotherapy (5.6% per yr, p < 0.001). Risk of any new CCI change after ADT was greater for GnRH agonists than for AA (hazard ratio, 1.32; 95% confidence interval, 1.20-144). Conclusions: Impact on comorbidity was lower for men on AA monotherapy than for men on GnRH agonists. Our results should be confirmed through randomised trials of effectiveness and adverse effects, comparing AA monotherapy and GnRH agonists in men with advanced nonmetastatic PCa who are unsuitable for curative treatment. Patient summary: Hormone therapies for advanced prostate cancer can increase the risk of other diseases (eg, heart disease, diabetes). This study compared two common forms of hormone therapy and found that the risk of another serious disease was higher for those on gonadotropin-r
- Published
- 2019
- Full Text
- View/download PDF
424. Reply to Jon Mikel Inarritu, Daniele Castellani, and Jeremy YC Teoh's Letter to the Editor re: Agustina Bessa, Steven Maclennan, Deborah Enting, et al. Consensus in Bladder Cancer Research Priorities Between Patients and Healthcare Professionals Using a Four-stage Modified Delphi Method. Eur Urol 2019;76:260-1
- Author
-
Bessa, Agustina, Maclennan, Steven, Enting, Deborah, Bryan, Richard, Häggström, Christel, Van Hemelrijck, Mieke, Bessa, Agustina, Maclennan, Steven, Enting, Deborah, Bryan, Richard, Häggström, Christel, and Van Hemelrijck, Mieke
- Published
- 2019
- Full Text
- View/download PDF
425. Selenium and sex steroid hormones in a US nationally representative sample of men: A role for the link between selenium and estradiol in prostate carcinogenesis?
- Author
-
Van Hemelrijck, Mieke, Sollie, Sam, Nelson, William G, Yager, James D, Kanarek, Norma F, Dobs, Adrian, Platz, Elizabeth A, Rohrmann, Sabine; https://orcid.org/0000-0002-2215-1200, Van Hemelrijck, Mieke, Sollie, Sam, Nelson, William G, Yager, James D, Kanarek, Norma F, Dobs, Adrian, Platz, Elizabeth A, and Rohrmann, Sabine; https://orcid.org/0000-0002-2215-1200
- Abstract
BACKGROUND Given the recent findings from pooled studies about a potential inverse association between selenium levels and prostate cancer risk, the current cross-sectional study aimed to investigate the association between serum selenium and serum concentrations of sex steroid hormones including estradiol in a nationally representative sample of US men to investigate one mechanism by which selenium may influence prostate cancer risk. METHODS The study included 1,420 men aged 20 years or older who participated in the Third National Health and Nutrition Examination Survey (NHANES III) between 1988 and 1994. We calculated age/race-ethnicity-adjusted and multivariable-adjusted geometric mean serum concentrations of total and estimated free testosterone and estradiol, androstanediol glucuronide (AAG), and sex hormone binding globulin (SHBG) and compared them across quartiles of serum selenium. RESULTS Adjusting for age, race/ethnicity, smoking status, serum cotinine, household income, physical activity, alcohol consumption and percent body fat, mean total estradiol (e.g. Q1:38.00 pg/mL (95%CI:36.03-40.08) vs Q4:35.29 pg/mL (33.53-37.14); Ptrend=0.050)and free estradiol [e.g.Q1: 0.96 pg/mL (95%CI: 0.92-1.01) vs Q4: 0.90 (95%CI:0.85-0.95); Ptrend=0.065] concentrations decreased over quartiles of selenium. Stratification by smoking and alcohol consumption, showed that the latter observation was stronger for never smokers (Pinteraction=0.073) and those with limited alcohol intake (Pinteraction=0.017). No associations were observed for the other sex steroid hormones studied. CONCLUSION Our findings suggests that a possible mechanism by which selenium may be protective for prostate cancer is related to estrogen. IMPACT Further studies of longitudinal measurements of serum and toenail selenium in relation to serum measurements of sex steroid hormones are needed.
- Published
- 2019
426. The experience of UK patients with bladder cancer during the second wave of the COVID‐19 pandemic.
- Author
-
Russell, Beth, Spencer‐Bowdage, Sarah, Rigby, Jeannie, O'Kelly, Jackie, Kelly, Phil, Page, Mark, Raw, Caroline, Allchorne, Paula, Harper, Peter, Crew, Jeremy, Kockelbergh, Roger, Knight, Allen, Van Hemelrijck, Mieke, and Bryan, Richard T.
- Published
- 2022
- Full Text
- View/download PDF
427. Validation and reliability of the Dutch version of the EORTC QLQ-NMIBC24 Questionnaire Module for patients with non-muscle-invasive bladder cancer.
- Author
-
Ripping, Theodora M., Westhoff, Ellen, Aaronson, Neil K., Van Hemelrijck, Mieke, Rammant, Elke, Witjes, J. Alfred, Kiemeney, Lambertus. A., Aben, Katja K. H., and Vrieling, Alina
- Subjects
BLADDER cancer ,CANCER invasiveness ,QUALITY of life ,PSYCHOMETRICS ,QUESTIONNAIRES ,EXPERIMENTAL design ,RESEARCH evaluation ,STATISTICAL reliability ,CONFIDENCE intervals ,RESEARCH methodology evaluation ,RESEARCH methodology ,DISCRIMINANT analysis ,NON-muscle invasive bladder cancer ,MULTITRAIT multimethod techniques ,CRONBACH'S alpha ,FACTOR analysis ,INTRACLASS correlation ,DESCRIPTIVE statistics ,RECEIVER operating characteristic curves ,TRANSLATIONS - Abstract
Background: The European Organisation for Research and Treatment of Cancer (EORTC) quality of life questionnaire for non-muscle invasive bladder cancer (QLQ-NMIBC24) has been available and applied for some years now, but has yet to undergo a full comprehensive psychometric evaluation. The aim of this study was to investigate the psychometric properties of the Dutch version of the EORTC QLQ-NMIBC24 questionnaire in patients with low, intermediate and high risk NMIBC. Methods: We included patients newly diagnosed with NMIBC participating in the multicenter, population-based prospective cohort studies UroLife or BlaZIB. Psychometric evaluation included examination of the structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-groups validity), responsiveness and interpretability. Results: A total of 1463 patients who completed the baseline questionnaire of UroLife (n = 541, response rate 50%) or BlaZIB (n = 922, response rate 58%) were included. The percentage of missing responses were low for all non-sex related scales (< 1%) and ranged between 6.9% to 50.0% for sex-related scales. More than 15% of the patients obtained the lowest possible scores on nearly each scale (floor effect). The structural validity was adequate; the confirmatory factor analysis showed satisfactory results and all items of multiple items scales had higher within- than between-scale correlations. Reliability of the questionnaire was adequate for most multiple item scales (Cronbach's α ≥ 0.70 and intraclass correlation coefficient ≥ 0.70), with exception of the scales 'malaise' and 'bloating and flatulence'. The questionnaire also showed good construct validity; it showed low correlations with the items of the EORTC core questionnaire and was able to measure differences between risk-based subgroups. The responsiveness of the questionnaire was good, but the interpretability, i.e. minimal important change, could not be determined. Conclusions: This study shows that the measurement properties of the EORTC QLQL-NMIBC24 are good; it has a good structural validity, reliability (i.e. internal consistency and test–retest reliability), construct validity (i.e. divergent validity and known-group validity), and responsiveness. Interpretability could not be assessed. This questionnaire can be used to measure and monitor health-related quality of life of patients with NMIBC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
428. Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study.
- Author
-
Santaolalla, Aida, Sollie, Sam, Rislan, Ali, Josephs, Debra H., Hammar, Niklas, Walldius, Goran, Garmo, Hans, Karagiannis, Sophia N., and Van Hemelrijck, Mieke
- Subjects
BIOMARKERS ,MULTIVARIATE analysis ,IMMUNE system ,LEUCOCYTES ,IMMUNOGLOBULIN G ,HEPATORENAL syndrome - Abstract
Background: Although the onset of inflammatory cascades may profoundly influence the nature of antibody responses, the interplay between inflammatory and humoral (antibody) immune markers remains unclear. Thus, we explored the reciprocity between the humoral immune system and inflammation and assessed how external socio-demographic factors may influence these interactions. From the AMORIS cohort, 5513 individuals were identified with baseline measurements of serum humoral immune [immunoglobulin G, A & M (IgG, IgA, IgM)] and inflammation (C-reactive protein (CRP), albumin, haptoglobin, white blood cells (WBC), iron and total iron-binding capacity) markers measured on the same day. Correlation analysis, principal component analysis and hierarchical clustering were used to evaluate biomarkers correlation, variation and associations. Multivariate analysis of variance was used to assess associations between biomarkers and educational level, socio-economic status, sex and age. Results: Frequently used serum markers for inflammation, CRP, haptoglobin and white blood cells, correlated together. Hierarchical clustering and principal component analysis confirmed the interaction between these main biological responses, showing an acute response component (CRP, Haptoglobin, WBC, IgM) and adaptive response component (Albumin, Iron, TIBC, IgA, IgG). A socioeconomic gradient associated with worse health outcomes was observed, specifically low educational level, older age and male sex were associated with serum levels that indicated infection and inflammation. Conclusions: These findings indicate that serum markers of the humoral immune system and inflammation closely interact in response to infection or inflammation. Clustering analysis presented two main immune response components: an acute and an adaptive response, comprising markers of both biological pathways. Future studies should shift from single internal marker assessment to multiple humoral and inflammation serum markers combined, when assessing risk of clinical outcomes such as cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
429. The importance of patient and public involvement in cancer research: time to create a new job profile.
- Author
-
Van Hemelrijck, Mieke, Peters, Vivienne, Loong, John F, Russell, Beth, Fox, Louis, Wylie, Harriet, Santaolalla, Aida, Beyer, Katharina, Rammant, Elke, Lin, E, Haire, Anna, Moss, Charlotte, and Green, Saran
- Subjects
FERRANS & Powers Quality of Life Index ,PATIENT participation ,JOB Descriptive Index ,RESEARCH funding ,ONCOLOGY ,MEDICAL research - Abstract
Tweetable abstract Need to add #PPI coordinator to required job profiles in #research: improve research quality, enthuse research team and ensure #patients and their families are the center of our research activities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
430. The incidence and prevalence of upper tract urothelial carcinoma: a systematic review.
- Author
-
Soualhi, Ahmed, Rammant, Elke, George, Gincy, Russell, Beth, Enting, Deborah, Nair, Rajesh, Van Hemelrijck, Mieke, and Bosco, Cecilia
- Subjects
TRANSITIONAL cell carcinoma ,PUBLIC health ,ADULTS ,MEDICAL personnel ,BLADDER cancer ,DATA extraction - Abstract
Background: Upper tract urothelial carcinoma (UTUC) is a rare urological cancer that is still an important public health concern in many areas around the world. Although UTUC has been linked to a number of risk factors, to our knowledge no systematic review has been published on the overall incidence and prevalence of de-novo UTUC. This review aimed to examine the global epidemiology of UTUC to provide clinicians and public health specialists a better understanding of UTUC.Methods: A systematic search was conducted on MEDLINE, Embase, and the Web of Science using a detailed search strategy. Observational epidemiological studies describing the incidence and prevalence of de-novo UTUC in adults were included, and the Joanna Briggs Institute checklist was used for critical appraisal and data extraction of the studies selected.Results: The systematic search identified 3506 papers, of which 59 papers were included for qualitative synthesis. The studies selected included data ranging from the years 1943 to 2018. A comprehensive qualitative synthesis of the data was performed. UTUC incidence generally varied according to age (higher with increasing age), sex (unclear), race (unclear), calendar time (increased, stable, or decreased according to region), geographical region (higher in Asian countries), occupation (higher in seamen and printers), and other population characteristics. Prevalence was only reported by one study, which showed UTUC to have the highest incidence of the rare urogenital cancers in Europe.Conclusion: This systematic review highlights an increased incidence of UTUC in certain groups, including increasing age and certain occupations such as seamen. The incidence of UTUC also varies between certain geographical regions. The trend of UTUC incidence for sex, race, and calendar time is less clear due to a wide variety of metrics used by the studies identified. More studies are also required on the prevalence of UTUC to understand its disease burden. Trial registration This review was registered on PROSPERO (registration number CRD42019134255). [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
431. Limb volume reduction and infection outcomes following vascularized lymph node transfer for cancer treatment-related lymphoedema: a systematic review and meta-analysis
- Author
-
Ward, Joseph, King, Ian, Monroy-Inglesias, Maria, Russell, Beth, Van Hemelrijck, Mieke, Ramsey, Kelvin, and Khan, Aadil
- Published
- 2022
- Full Text
- View/download PDF
432. Global cancer research in the era of COVID-19: a bibliometric analysis.
- Author
-
Van Hemelrijck, Mieke, Lewison, Grant, Fox, Louis, Vanderpuye, Verna D. N. K., Murillo, Raúl, Booth, Chris M., Canfell, Karen, Pramesh, C. S., Sullivan, Richard, and Mukherij, Deborah
- Subjects
- *
COVID-19 , *COVID-19 pandemic , *CANCER research , *LOW-income countries , *HIGH-income countries - Abstract
Background: Patients with cancer across the world have been impacted by the COVID-19 pandemic due to increased risk of infection and disruption to cancer diagnosis and treatment. Widening of healthcare disparities is expected as the gap between health systems with and without adequate resources to mitigate the pandemic become more apparent. We undertook a bibliometric analysis of research related to cancer and COVID-19 to understand (1) the type of research that has been conducted (e.g. patients, services and systems) and (2) whether the pandemic has impacted the state of global cancer research as measured by research outputs to date. Methods: An existing filter for cancer research consisting of title words and the names of specialist cancer journals was used to identify cancer and COVID-19 related articles and reviews in the Web of Science (©Clarivate Analytics) between January 2019 and February 2021. Results: One thousand five hundred and forty-five publications were identified. The majority (57%) were reviews, opinion pieces or concerned with modelling impact of delays to diagnosis and treatment. The main research domains focused on managing or estimating COVID-19 risk to cancer patients accounting for 384 papers (25%). High Income countries contributed the largest volume (n = 1,115; 72%), compared to Upper Middle (n = 302; 20%), Lower Middle (n = 122; 8%) and Low Income countries (n = 2.4; 0.2%). No evidence of a reduction in global cancer research output was observed in 2020. Conclusions: We observed a shift in research focus rather than a decline in absolute output. However, there is variation based on national income and collaborations are minimal. There has been a focus on pan-cancer studies rather than cancer site-specific studies. Strengthening global multidisciplinary research partnerships with teams from diverse backgrounds with regard to gender, clinical expertise and resource setting is essential to prevent the widening of cancer inequalities. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
433. Negative first follow‐up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
- Author
-
Singh, Sohail, Sandhu, Preeti, Beckmann, Kerri, Santaolalla, Aida, Dewan, Kamal, Clovis, Sharon, Rusere, Jonah, Zisengwe, Grace, Challacombe, Benjamin, Brown, Christian, Cathcart, Paul, Popert, Rick, Dasgupta, Prokar, Van Hemelrijck, Mieke, and Elhage, Oussama
- Subjects
PROSTATE cancer ,PROSTATE biopsy ,MAGNETIC resonance imaging ,PROSTATE-specific antigen ,SUSPICION ,DISEASE progression - Abstract
Objective: To determine the risk of disease progression and conversion to active treatment following a negative biopsy while on active surveillance (AS) for prostate cancer (PCa). Patients and Methods: Men on an AS programme at a single tertiary hospital (London, UK) between 2003 and 2018 with confirmed low–intermediate‐risk PCa, Gleason Grade Group <3, clinical stage
30% positive cores, magnetic resonance imaging (MRI) Likert score >3/T3 or PSA level of >20 ng/mL. Conversion to treatment included radical or hormonal treatment. Results: Among the 460 eligible patients, 23% had negative follow‐up biopsy findings. The median follow‐up was 62 months, with one to two repeat biopsies and two MRIs per patient during that period. Negative biopsy findings at first repeat biopsy were associated with decreased risk of converting to active treatment (hazard ration [HR] 0.18, 95% confidence interval [CI] 0.09–0.37; P < 0.001), suspicion of disease progression (HR 0.56, 95% CI: 0.34–0.94; P = 0.029), and upgrading (HR 0.48, 95% CI 0.23–0.99; P = 0.047). Data are limited by fewer men with multiple follow‐up biopsies. Conclusion: A negative biopsy finding at the first scheduled follow‐up biopsy among men on AS for PCa was strongly associated with decreased risk of subsequent upgrading, clinical or radiological suspicion of disease progression, and conversion to active treatment. A less intense surveillance protocol should be considered for this cohort of patients. [ABSTRACT FROM AUTHOR] - Published
- 2021
- Full Text
- View/download PDF
434. Exploring a role for fatty acid synthase in prostate cancer cell migration.
- Author
-
De Piano, Mario, Manuelli, Valeria, Zadra, Giorgia, Loda, Massimo, Muir, Gordon, Chandra, Ash, Morris, Jonathan, Van Hemelrijck, Mieke, and Wells, Claire M.
- Subjects
CANCER cell migration ,PROSTATE cancer ,FATTY acids ,CANCER cell motility ,CELL migration ,ANDROGEN receptors - Abstract
Fatty acid synthase (FASN) is commonly overexpressed in prostate cancer and associated with tumour progression. FASN is responsible for de novo synthesis of the fatty acid palmitate; the building block for protein palmitoylation. A functional role for FASN in regulating cell proliferation is widely accepted. We recently reported that FASN activity can also mediate prostate cancer HGF-mediated cell motility. Moreover, we found that modulation of FASN expression specifically impacts on the palmitoylation of RhoU. Findings we will describe here. We now report that loss of FASN expression also impairs HGF-mediated cell dissociation responses. Taken together our results provide compelling evidence that FASN activity directly promotes cell migration and supports FASN as a potential therapeutic target in metastatic prostate cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
435. Guy's and St Thomas NHS Foundation active surveillance prostate cancer cohort: a characterisation of a prostate cancer active surveillance database.
- Author
-
Shah, Salonee, Beckmann, Kerri, Van Hemelrijck, Mieke, Challacombe, Ben, Popert, Rick, Dasgupta, Prokar, Rusere, Jonah, Zisengwe, Grace, Elhage, Oussama, and Santaolalla, Aida
- Subjects
PROSTATE cancer ,MAGNETIC resonance imaging ,PROSTATE-specific antigen ,DIAGNOSTIC ultrasonic imaging ,DIAGNOSIS ,GLEASON grading system - Abstract
Background: The routine clinical use of serum prostatic specific antigen (PSA) testing has allowed earlier detection of low-grade prostate cancer (PCa) with more favourable characteristics, leading to increased acceptance of management by active surveillance (AS). AS aims to avoid over treatment in men with low and intermediate-risk PCa and multiple governing bodies have described several AS protocols. This study provides a descriptive profile of the Guy's and St Thomas NHS Foundation Trust (GSTT) AS cohort as a platform for future research in AS pathways in PCa.Methods: Demographic and baseline characteristics were retrospectively collected in a database for patients at the GSTT AS clinic with prospective collection of follow-up data from 2012. Seven hundred eighty-eight men being monitored at GSTT with histologically confirmed intermediate-risk PCa, at least 1 follow-up appointment and diagnostic characteristics consistent with AS criteria were included in the profile. Descriptive statistics, Kaplan-Meier survival curves and multivariable Cox proportion hazards regression models were used to characterize the cohort.Discussion: A relatively large proportion of the cohort includes men of African/Afro-Caribbean descent (22%). More frequent use of magnetic resonance imaging and trans-perineal biopsies at diagnosis was observed among patients diagnosed after 2012. Those who underwent trans-rectal ultrasound diagnostic biopsy received their first surveillance biopsy 20 months earlier than those who underwent trans-perineal diagnostic biopsy. At 3 years, 76.1% men remained treatment free. Predictors of treatment progression included Gleason score 3 + 4 (Hazard ratio (HR): 2.41, 95% Confidence interval (CI): 1.79-3.26) and more than 2 positive cores taken at biopsy (HR: 2.65, CI: 1.94-3.62). A decreased risk of progressing to treatment was seen among men diagnosed after 2012 (HR: 0.72, CI: 0.53-0.98).Conclusion: An organised biopsy surveillance approach, via two different AS pathways according to the patient's diagnostic method, can be seen within the GSTT cohort. Risk of patients progressing to treatment has decreased in the period since 2012 compared with the prior period with more than half of the cohort remaining treatment free at 5 years, highlighting that the fundamental aims of AS at GSTT are being met. Thus, this cohort is a good resource to investigate the AS treatment pathway. [ABSTRACT FROM AUTHOR]- Published
- 2021
- Full Text
- View/download PDF
436. Risk of cardiovascular disease following gonadotropin‐releasing hormone agonists vs antagonists in prostate cancer: Real‐world evidence from five databases.
- Author
-
George, Gincy, Garmo, Hans, Scailteux, Lucie‐Marie, Balusson, Frédéric, De Coster, Greet, De Schutter, Harlinde, Kuiper, Josephina G., Oger, Emmanuel, Verbeeck, Julie, and Van Hemelrijck, Mieke
- Subjects
CARDIOVASCULAR diseases ,PROSTATE cancer ,MYOCARDIAL infarction ,PROPORTIONAL hazards models - Abstract
Observational studies in prostate cancer (PCa) have shown an increased risk of cardiovascular disease (CVD) following gonadotropin‐releasing hormone (GnRH) agonists, whereas randomised‐controlled trials have shown no associations. Compared to GnRH agonists, GnRH antagonists have shown less atherosclerotic effects in preclinical models. We used real‐world data from five countries to investigate CVD risk following GnRH agonists and antagonists in PCa men. Data sources included cancer registries, primary and secondary healthcare databases. CVD event was defined as an incident or fatal CVD. Multivariable Cox proportional hazard models estimated hazard ratios (HRs) and 95% confidence intervals (CIs), which were pooled using random‐effects meta‐analysis. Stratified analyses were conducted by history of CVD and age (75 years). A total of 48 757 men were on GnRH agonists and 2144 on GnRH antagonists. There was no difference in risk of any CVD for men on GnRH antagonists and agonists (HR: 1.25; 95% CI: 0.96‐1.61; I2: 64%). Men on GnRH antagonists showed increased risk of acute myocardial infarction (HR: 1.62; 95% CI: 1.11‐2.35; I2: 0%) and arrhythmia (HR: 1.55; 95% CI: 1.11‐2.15, I2: 17%) compared to GnRH agonists. Having a history of CVD was found to be an effect modifier for the associations with some CVD subtypes. Overall, we did not observe a difference in risk of overall CVD when comparing GnRH antagonists with agonists—though for some subtypes of CVD we noted an increased risk with antagonists. Further studies are required to address potential confounding caused by unadjusted variables such as severity of CVD history and PCa stage. What's new? Prolonged use of gonadotropin‐releasing hormone (GnRH) agonists has been associated with an increased risk of cardiovascular disease (CVD). Preclinical studies have indicated that newer GnRH antagonists may cause fewer atherosclerotic effects than GnRH agonists. In this meta‐analysis of prostate cancer studies, however, the authors found little benefit of GnRH antagonists over GnRH agonists, in terms of CVD risk. If anything, men taking GnRH antagonists may have an increased risk of acute myocardial infarction and arrhythmia compared to GnRH agonists. Further studies are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
437. Adjuvant therapy following neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma in patients with clear resection margins.
- Author
-
Bott, Rebecca K., Beckmann, Kerri, Zylstra, Janine, Wilkinson, Michelle J., Knight, William R. C., Baker, Cara R., Kelly, Mark, Maisey, Nick, Waters, Justin, Van Hemelrijck, Mieke, Smyth, Elizabeth C., Allum, William H., Lagergren, Jesper, Gossage, James A., Cunningham, David, and Davies, Andrew R.
- Subjects
ADENOCARCINOMA ,CONFIDENCE intervals ,MULTIPLE regression analysis ,RETROSPECTIVE studies ,SURGICAL margin ,TREATMENT effectiveness ,ADJUVANT treatment of cancer ,CHEMORADIOTHERAPY ,INTERPROFESSIONAL relations ,SURVIVAL analysis (Biometry) ,COMBINED modality therapy ,ESOPHAGEAL tumors ,LONGITUDINAL method ,PROPORTIONAL hazards models - Abstract
The role of adjuvant therapy in patients with oesophagogastric adenocarcinoma treated by neoadjuvant chemotherapy (NAC) and surgery is contentious. In UK practice, surgical resection margin status is often used to classify patients into receiving adjuvant treatment. This study aimed to assess any survival benefit of adjuvant therapy in patients with clear resection margins. This was a retrospective collaborative cohort study combining two prospectively collected UK institutional databases of patients with oesophageal adenocarcinoma. Multivariable Cox regression and propensity matched analyses were used to compare overall and recurrence-free survival according to the adjuvant treatment. Of 374 patients with clear resection margins, 221 patients (59%) had no adjuvant treatment, 137 patients (37%) had adjuvant chemotherapy and 16 patients (4%) had adjuvant chemoradiotherapy. For patients who had received NAC (290, 76%), when adjuvant chemotherapy was compared to no adjuvant treatment, hazard ratios (HRs) favoured adjuvant chemotherapy but did not reach independent significance (overall survival [OS] HR 0.65 95% confidence interval [CI] 0.40–1.06; p.0.087). Responders to NAC (Mandard 1–3) were seemingly more likely to demonstrate a survival benefit from adjuvant chemotherapy (HR 0.42 95% CI 0.15–1.11; p.1.081). Although no independent survival benefit was observed, the point estimates favoured adjuvant treatment, predominantly in patients with chemo-responsive tumours. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
438. Ability of a biomarker-based score to predict death from circulatory disease and cancer in NHANES III
- Author
-
Van Hemelrijck Mieke, Eichholzer Monika, Faeh David, and Rohrmann Sabine
- Subjects
Mortality ,Albumin ,HDL-cholesterol ,C-reactive protein ,Gamma-glutamyltransferase ,Public aspects of medicine ,RA1-1270 - Abstract
Abstract Background A score based on serum concentrations of C-reactive protein (CRP), albumin, gamma-glutamyl transferase (GGT), and HDL cholesterol was positively associated with death from cancer, circulatory disease, and all-cause mortality. We replicated this in the third National Health and Nutrition Examination Survey (NHANES III), a US nationally representative survey conducted between 1988–1994. Methods Baseline measurements of CRP, albumin, GGT, and HDL were available for participants with mortality follow-up (n=13,056). A biomarker score, ranging 0–4, was created by adding number of markers with abnormal values (cut-off: CRP>10mg/L, albumin36U/L, HDL Results The score was positively associated with death from all causes, cancer and circulatory disease [e.g. HR all-cause mortality: 1.21 (95% CI: 1.09, 1.35), 1.92 (1.67, 2.20), 3.38 (2.62, 4.36), and 7.93 (5.77, 10.89), for score 1, 2, 3, 4 vs.0]. These patterns were found across the Charlson Comorbidity Index (CCI). Where CCI =3, risk of cancer death was 1.09 (0.93, 1.28), 1.81 (1.43, 2.29), 4.67 (3.05, 7.14), and 6.97 (5.32, 9.14) for score 1, 2, 3, 4 vs. 0. No effect-modification by sex or race/ethnicity was observed. Conclusions These findings correlate with results from a Swedish study. This biomarker-based score could help clinicians make decisions in prevention and disease management.
- Published
- 2012
- Full Text
- View/download PDF
439. Heterogeneity in risk of prostate cancer:A Swedish population-based cohort study of competing risks and type 2 diabetes mellitus
- Author
-
Häggström, Christel, Van Hemelrijck, Mieke, Garmo, Hans Gunnar, Robinson, D, Stattin, P, Rowley, Mark Ian, Coolen, ACC, and Holmberg, Lars Hjalmar
- Abstract
Most previous studies of prostate cancer have not taken into account that men in the studied populations are also at risk of competing event, and that these men may have different susceptibility to prostate cancer risk. The aim of our study was to investigate heterogeneity in risk of prostate cancer, using a recently developed latent class regression method for competing risks. We further aimed to elucidate the association between Type 2 diabetes mellitus (T2DM) and prostate cancer risk, and to compare the results with conventional methods for survival analysis. We analysed the risk of prostate cancer in 126,482 men from the comparison cohort of the Prostate Cancer Data base Sweden (PCBaSe) 3.0. During a mean follow‐up of 6 years 6,036 men were diagnosed with prostate cancer and 22,393 men died. We detected heterogeneity in risk of prostate cancer with two distinct latent classes in the study population. The smaller class included 9% of the study population in which men had a higher risk of prostate cancer and the risk was stronger associated with class membership than any of the covariates included in the study. Moreover, we found no association between T2DM and risk of prostate cancer after removal of the effect of informative censoring due to competing risks. The recently developed latent class for competing risks method could be used to provide new insights in precision medicine with the target to classify individuals regarding different susceptibility to a particular disease, reaction to a risk factor or response to treatment.
- Published
- 2018
440. Systematic identification of functionally relevant risk alleles to stratify aggressive versus indolent prostate cancer
- Author
-
Nowinski, Salpie Elena, Santa Olalla, Aida, O’Leary, Ben, Loda, Massimo, Mirchandani, Ayesha, Emberton, Mark, Van Hemelrijck, Mieke, and Grigoriadis, Anita
- Abstract
Novel approaches for classification, including molecular features, are needed to direct therapy for men with low-grade prostate cancer (PCa), especially men on active surveillance. Risk alleles identified from genome-wide association studies (GWAS) could improve prognostication. Those risk alleles that coincided with genes and somatic copy number aberrations associated with progression of PCa were selected as the most relevant for prognostication.In a systematic literature review, a total of 698 studies were collated. Fifty- three unique SNPs residing in 29 genomic regions, including 8q24, 10q11 and 19q13, were associated with PCa progression. Functional studies implicated 21 of these single nucleotide polymorphisms (SNPs) as modulating the expression of genes in the androgen receptor pathway and several other oncogenes. In particular, 8q24, encompassing MYC, harbours a high density of SNPs conferring unfavourable pathological characteristics in low-grade PCa, while a copy number gain of MYC in low-grade PCa was associated with prostate-specific antigen recurrence after radical prostatectomy.By combining GWAS data with gene expression and structural rearrangements, risk alleles were identified that could provide a new basis for developing a prognostication tool to guide therapy for men with early prostate cancer.
- Published
- 2018
441. Heterogeneity in risk of prostate cancer : A Swedish population-based cohort study of competing risks and Type 2 diabetes mellitus
- Author
-
Häggström, Christel, Van Hemelrijck, Mieke, Garmo, Hans, Robinson, David, Stattin, Pär, Rowley, Mark, Coolen, Anthony C. C., and Holmberg, Lars
- Subjects
Aged, 80 and over ,Male ,Sweden ,Cancer och onkologi ,Prostatic Neoplasms ,latent class ,Middle Aged ,prostate cancer ,Survival Analysis ,survival analysis ,Cohort Studies ,Diabetes Mellitus, Type 2 ,Research Design ,Risk Factors ,Cancer and Oncology ,Type 2 diabetes mellitus ,Humans ,Cancer Epidemiology ,Aged ,competing risks - Abstract
Most previous studies of prostate cancer have not taken into account that men in the studied populations are also at risk of competing event, and that these men may have different susceptibility to prostate cancer risk. The aim of our study was to investigate heterogeneity in risk of prostate cancer, using a recently developed latent class regression method for competing risks. We further aimed to elucidate the association between Type 2 diabetes mellitus (T2DM) and prostate cancer risk, and to compare the results with conventional methods for survival analysis. We analysed the risk of prostate cancer in 126,482 men from the comparison cohort of the Prostate Cancer Data base Sweden (PCBaSe) 3.0. During a mean follow‐up of 6 years 6,036 men were diagnosed with prostate cancer and 22,393 men died. We detected heterogeneity in risk of prostate cancer with two distinct latent classes in the study population. The smaller class included 9% of the study population in which men had a higher risk of prostate cancer and the risk was stronger associated with class membership than any of the covariates included in the study. Moreover, we found no association between T2DM and risk of prostate cancer after removal of the effect of informative censoring due to competing risks. The recently developed latent class for competing risks method could be used to provide new insights in precision medicine with the target to classify individuals regarding different susceptibility to a particular disease, reaction to a risk factor or response to treatment., What's new? Men with type 2 diabetes have a decreased risk of developing prostate cancer but metabolic disease is associated with a shorter life expectancy. Here the authors applied a new method to handle competing risks and cohort heterogeneity and found no association between type 2 diabetes mellitus and prostate cancer risk after isolating the effect from competing risks. This method may support precision medicine by correctly classifying individuals regarding susceptibility to a particular cancer or response to treatment.
- Published
- 2018
442. Determinants of cancer screening awareness and participation among Indonesian women
- Author
-
Anwar, Sumadi L., Tampubolon, Gindo, Van Hemelrijck, Mieke, Hutajulu, Susanna H., Watkins, Johnathan, and Wulaningsih, Wahyu
- Subjects
Adult ,pap smear ,Health Knowledge, Attitudes, Practice ,ResearchInstitutes_Networks_Beacons/global_development_institute ,cervical cancer ,Uterine Cervical Neoplasms ,Breast Neoplasms ,breast self-examination ,Breast cancer ,breast cancer ,Pap smears ,Humans ,Early Detection of Cancer ,Vaginal Smears ,screening ,Breast Self-Examination ,Middle Aged ,Patient Acceptance of Health Care ,Prognosis ,Global Development Institute ,Indonesia ,Population Surveillance ,Screening ,Cervical cancer ,Female ,Research Article ,Follow-Up Studies - Abstract
Background Cancer screening awareness and participation may be lower in low- and middle-income countries that lack established national screening programmes compared with those that do. We evaluated potential determinants of awareness about and participation in breast and cervical cancer screening, and breast self-examination (BSE) in women using survey data from Indonesia. Methods From the fifth Indonesian Family Life Survey (2014–2015), a total of 5397 women aged 40 and older without any history of cancer who responded to questionnaires concerning Pap smears, mammography, and BSE were included. Multilevel modelling was used to assess potential determinants in relation to awareness about Pap smears and mammography, and participation in Pap smears and BSE practice. Multivariable analyses were performed to identify independent predictors of cancer screening. Results Of the 5397 respondents, 1058 (20%) women were aware of Pap smears, of which 297 had never had the procedure. Only 251 (5%) participants were aware of mammography. A total of 605 (12%) of women reported they performed BSE. Higher education and household expenditure were consistently associated with higher odds of awareness about Pap smears and mammography (e.g. odds ratio [OR] of being aware of Pap smear and mammography: 7.82 (95% CI: 6.30–9.70) and 7.70 (6.19–9.58), respectively, for high school graduates compared to women with less educational attainment in the multivariable models), and participation in Pap smears and BSE. We also identified enabling factors linked with greater cancer screening awareness and participation, including health insurance, shorter distance to health services, and social participation. Conclusion There are socioeconomic disparities in cancer screening awareness and participation among Indonesian women. Our findings may help inform targeted health promotion and screening for cancer in the presence of limited resources. Electronic supplementary material The online version of this article (10.1186/s12885-018-4125-z) contains supplementary material, which is available to authorized users.
- Published
- 2018
443. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date
- Author
-
Bruinsma, Sophie M, Zhang, Liying, Roobol, Monique J, Bangma, Chris H, Steyerberg, Ewout W, Nieboer, Daan, Van Hemelrijck, Mieke, and Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) Consortium
- Subjects
Aged, 80 and over ,Male ,Time Factors ,Databases, Factual ,Prostatic Neoplasms ,Middle Aged ,Prognosis ,Global Health ,Risk Assessment ,Time-to-Treatment ,Cohort Studies ,Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) consortium ,Charities ,Disease Progression ,Humans ,Public Health Surveillance ,Men's Health ,Watchful Waiting ,Early Detection of Cancer ,Aged - Abstract
The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. PATIENTS AND METHODS: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. RESULTS: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60-70) years and the median prostate-specific antigen level was 5.4 (4.0-7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0-5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. CONCLUSIONS: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.
- Published
- 2018
- Full Text
- View/download PDF
444. The Movember Foundation's GAP3 cohort: a profile of the largest global prostate cancer active surveillance database to date
- Author
-
Bruinsma, Sophie M., Zhang, Liying, Roobol, Monique J., Bangma, Chris H., Steyerberg, Ewout W., Nieboer, Daan, Van Hemelrijck, Mieke, Trock, Bruce, Ehdaie, Behfar, Carroll, Peter, Filson, Christopher, Kim, Jeri, Morgan, Todd, Klotz, Laurence, Pickles, Tom, Hyndman, Eric, Moore, Caroline M., Gnanapragasam, Vincent, Dasgupta, Prokar, Villers, Arnauld, Rannikko, Antti, Valdagni, Riccardo, Perry, Antoinette, Hugosson, Jonas, Rubio-Briones, Jose, Bjartell, Anders, Hefermehl, Lukas, Lui Shiong, Lee, Frydenberg, Mark, Kakehi, Yoshiyuki, Ha Chung, Byung, van der Kwast, Theo, Obbink, Henk, van der Linden, Wim, Hulsen, Tim, de Jonge, Cees, Kattan, Mike, Xinge, Ji, Muir, Kenneth, Lophatananon, Artitaya, Fahey, Michael, Guo, Wei, Milan, Tanya, Benfante, Nicole, Cowan, Janet, Patil, Dattatraya, Sanford, Rachel, Kim, Tae Kyung, Mamedov, Alexandre, Santaolalla, Aida, Urology, and Public Health
- Subjects
Male ,Time Factors ,Databases, Factual ,Urology ,medicine.medical_treatment ,#PCSM ,030232 urology & nephrology ,computer.software_genre ,Global Health ,Risk Assessment ,Time-to-Treatment ,Cohort Studies ,03 medical and health sciences ,Prostate cancer ,0302 clinical medicine ,Quality of life ,SDG 3 - Good Health and Well-being ,evidence-based ,Interquartile range ,Medicine ,Humans ,Cumulative incidence ,Public Health Surveillance ,Watchful Waiting ,Early Detection of Cancer ,Aged ,Aged, 80 and over ,adenocarcinoma ,Database ,business.industry ,Prostatic Neoplasms ,Middle Aged ,medicine.disease ,Prognosis ,Discontinuation ,#ProstateCancer ,Charities ,030220 oncology & carcinogenesis ,Cohort ,Disease Progression ,business ,Men's Health ,guideline ,computer ,Watchful waiting ,Cohort study - Abstract
Objectives: The Movember Foundation launched the Global Action Plan Prostate Cancer Active Surveillance (GAP3) initiative to create a global consensus on the selection and monitoring of men with low-risk prostate cancer (PCa) on active surveillance (AS). The aim of this study is to present data on inclusion and follow-up for AS in this unique global AS database. Patients and Methods: Between 2014 and 2016, the database was created by combining patient data from 25 established AS cohorts worldwide (USA, Canada, Australasia, UK and Europe). Data on a total of 15 101 patients were included. Descriptive statistics were used to report patients' clinical and demographic characteristics at the time of PCa diagnosis, clinical follow-up, discontinuation of AS and subsequent treatment. Cumulative incidence curves were used to report discontinuation rates over time. Results: At diagnosis, the median (interquartile range [IQR]) patient age was 65 (60–70) years and the median prostate-specific antigen level was 5.4 (4.0–7.3) ng/mL. Most patients had clinical stage T1 disease (71.8%), a biopsy Gleason score of 6 (88.8%) and one tumour-positive biopsy core (60.3%). Patients on AS had a median follow-up time of 2.2 (1.0–5.0) years. After 5, 10 and 15 years of follow-up, respectively, 58%, 39% and 23% of patients were still on AS. The current version of GAP3 has limited data on magnetic resonance imaging (MRI), quality of life and genomic testing. Conclusions: GAP3 is the largest worldwide collaboration integrating patient data from men with PCa on AS. The results will allow individual patients and clinicians to have greater confidence in the personalized decision to either delay or proceed with active treatment. Longer follow-up and the evaluation of MRI, new genomic markers and patient-related outcomes will result in even more valuable data and eventually in better patient outcomes.
- Published
- 2018
445. Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study
- Author
-
Kessler, Anna, primary, Sollie, Sam, additional, Karagiannis, Sophia N., additional, Walldius, Goran, additional, Hammar, Niklas, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2019
- Full Text
- View/download PDF
446. Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort
- Author
-
Peppas, Ioannis, primary, Sollie, Sam, additional, Josephs, Debra H., additional, Hammar, Niklas, additional, Walldius, Göran, additional, Karagiannis, Sophia N., additional, and Van Hemelrijck, Mieke, additional
- Published
- 2019
- Full Text
- View/download PDF
447. Patient-reported outcomes in randomised clinical trials of bladder cancer: an updated systematic review
- Author
-
Van Hemelrijck, Mieke, primary, Sparano, Francesco, additional, Josephs, Debra, additional, Sprangers, Mirjam, additional, Cottone, Francesco, additional, and Efficace, Fabio, additional
- Published
- 2019
- Full Text
- View/download PDF
448. Graham Roberts Study protocol: first ‘trials within cohort study’ for bladder cancer
- Author
-
Wylie, Harriet, primary, Cahill, Fidelma, additional, Santaolalla, Aida, additional, Moss, Charlotte Louise, additional, Enting, Deborah, additional, Amery, Suzanne, additional, Chatterton, Kathryn, additional, Khan, Muhammad Shamim, additional, Bryan, Richard T, additional, Gillett, Cheryl, additional, Josephs, Debra, additional, Chowdhury, Simon, additional, Rudman, Sarah, additional, Hughes, Simon, additional, Relton, Clare, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2019
- Full Text
- View/download PDF
449. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study
- Author
-
Sollie, Sam, primary, Michaud, Dominique S., additional, Sarker, Debashis, additional, Karagiannis, Sophia N., additional, Josephs, Debra H., additional, Hammar, Niklas, additional, Santaolalla, Aida, additional, Walldius, Goran, additional, Garmo, Hans, additional, Holmberg, Lars, additional, Jungner, Ingmar, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2019
- Full Text
- View/download PDF
450. Is there any association between prostate-specific antigen screening frequency and uptake of active surveillance in men with low or very low risk prostate cancer?
- Author
-
Beckmann, Kerri, primary, Kinsella, Netty, additional, Olsson, Henrik, additional, Wallerstedt Lantz, Anna, additional, Nordstrom, Tobias, additional, Aly, Markus, additional, Adolfsson, Jan, additional, Eklund, Martin, additional, and Van Hemelrijck, Mieke, additional
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.